Callan JMB Inc. addresses a lawsuit, asserting claims are without merit and asserting focus on ongoing operations.
Quiver AI Summary
Callan JMB Inc. has issued a statement regarding a lawsuit filed against the company by Eddie Patent Holdings, LLC in the U.S. District Court for the Northern District of Texas. CEO Wayne Williams reported that the company is assessing the claims with legal counsel and considers them without merit, asserting that they will respond through appropriate legal channels. Callan JMB emphasized that the lawsuit does not affect its operations or ongoing projects, maintaining focus on long-term growth and service delivery in the healthcare logistics sector. The company has stated it will not provide further comments on the litigation but will update stakeholders as necessary.
Potential Positives
- Callan JMB asserts that the claims in the recent lawsuit are without merit, indicating confidence in their legal standing.
- The company emphasizes that the matter does not affect its operations, strategic partnerships, or ongoing projects, highlighting stability amidst legal challenges.
- Callan JMB is focused on advancing key initiatives and maintaining long-term growth, which suggests a proactive approach to business and resilience in their market.
Potential Negatives
- Callan JMB is facing a lawsuit that may introduce legal and financial uncertainties for the company.
- The statement acknowledges ongoing litigation, which may raise concerns among stakeholders about the company's potential liabilities and future operations.
- The press release does not provide details on the nature of the lawsuit, which may lead to speculation and uncertainty in the market about the company's reputation and integrity.
FAQ
What lawsuit was recently filed against Callan JMB?
A lawsuit was filed by Eddie Patent Holdings, LLC in the U.S. District Court for the Northern District of Texas.
How is Callan JMB responding to the lawsuit?
Callan JMB is reviewing the complaint with legal counsel and believes the claims are without merit.
Will the lawsuit affect Callan JMB's operations?
The company stated that the lawsuit does not impact its operations, strategic partnerships, or ongoing projects.
Who is the CEO of Callan JMB?
Wayne Williams is the Chief Executive Officer of Callan JMB.
What services does Callan JMB provide?
Callan JMB offers integrative logistics services, including fulfillment, storage, monitoring, and cold chain logistics for healthcare.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$CJMB Insider Trading Activity
$CJMB insiders have traded $CJMB stock on the open market 12 times in the past 6 months. Of those trades, 12 have been purchases and 0 have been sales.
Here’s a breakdown of recent trading of $CJMB stock by insiders over the last 6 months:
- WAYNE D WILLIAMS (CEO, Chairman and President) has made 6 purchases buying 65,343 shares for an estimated $109,257 and 0 sales.
- DAVID J CROYLE (Chief Medical Officer) has made 2 purchases buying 25,000 shares for an estimated $43,927 and 0 sales.
- GERALD DIAL has made 2 purchases buying 2,000 shares for an estimated $2,409 and 0 sales.
- LIBERTY SMITH DUKE has made 2 purchases buying 1,512 shares for an estimated $2,334 and 0 sales.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$CJMB Hedge Fund Activity
We have seen 7 institutional investors add shares of $CJMB stock to their portfolio, and 4 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- CABLE CAR CAPITAL, LP removed 392,586 shares (-75.0%) from their portfolio in Q4 2025, for an estimated $435,770
- BARD ASSOCIATES INC removed 114,989 shares (-29.1%) from their portfolio in Q4 2025, for an estimated $127,637
- CITADEL ADVISORS LLC added 44,002 shares (+inf%) to their portfolio in Q4 2025, for an estimated $48,842
- CREATIVE PLANNING added 35,685 shares (+21.0%) to their portfolio in Q4 2025, for an estimated $39,610
- UBS GROUP AG removed 27,390 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $30,402
- RENAISSANCE TECHNOLOGIES LLC added 11,400 shares (+inf%) to their portfolio in Q4 2025, for an estimated $12,654
- DRW SECURITIES, LLC added 10,296 shares (+inf%) to their portfolio in Q4 2025, for an estimated $11,428
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Full Release
Spring Branch, TX, April 17, 2026 (GLOBE NEWSWIRE) -- Callan JMB Inc. (NASDAQ: CJMB) (“Callan JMB” or the “Company”), an integrative logistics company empowering the healthcare industry and emergency management agencies through fulfillment, storage, monitoring, and cold chain logistics services, today issued a statement in response to a recently filed lawsuit in the U.S. District Court for the Northern District of Texas.
The complaint, filed by Eddie Patent Holdings, LLC, names Callan JMB among the defendants. The Company is currently reviewing the filing with legal counsel and believes the claims asserted in the complaint are without merit.
“While we take all legal matters seriously, we believe the claims asserted in the complaint are without merit and intend to respond through the appropriate legal process” said Wayne Williams, Chief Executive Officer of Callan JMB. “Because this is pending litigation, we do not intend to comment further at this time.”
Callan JMB emphasized that the matter does not impact its operations, strategic partnerships, or ongoing projects.
The Company continues to advance key initiatives and remains focused on long-term growth, operational execution, and delivering value to its stakeholders.
Callan JMB will provide updates as appropriate, but does not intend to comment further on active litigation.
About Callan JMB Inc.
Callan JMB Inc. is an integrative logistics company empowering the healthcare industry and emergency management agencies through fulfillment, storage, monitoring, and cold chain logistics services to secure medical materials and protect patients and communities with compliant, safe, and effective medicines. Our combined expertise in supply chain logistics, thermodynamics, biologics, inventory management, regulatory compliance, and emergency preparedness is unparalleled in the industry. We offer a gold standard in client experience with customizable interfaces, next-level reliability in shipping, and environmental sustainability in our specialty packaging.
Forward-Looking Statement
This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) (which Sections were adopted as part of the Private Securities Litigation Reform Act of 1995). Statements preceded by, followed by or that otherwise include the words “believe,” “anticipate,” “estimate,” “expect,” “intend,” “plan,” “project,” “prospects,” “outlook,” and similar words or expressions, or future or conditional verbs, such as “will,” “should,” “would,” “may,” and “could,” are generally forward-looking in nature and not historical facts. These forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the Company’s actual results, performance, or achievements to be materially different from any anticipated results, performance, or achievements for many reasons. The Company disclaims any intention to, and undertakes no obligation to, revise any forward-looking statements, whether as a result of new information, a future event, or otherwise. For additional risks and uncertainties that could impact the Company’s forward-looking statements, please see the Company’s Registration Statement Under the Securities Act of 1933 on Form S-1, including but not limited to the discussion under “Risk Factors” therein, which the Company filed with the SEC and which may be viewed at http://www.sec.gov/ .
Investor Contact:
Valter Pinto, Managing Director
KCSA Strategic Communications
[email protected]
212.896.1254